Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

Blood Cancer J. 2023 Mar 7;13(1):33. doi: 10.1038/s41408-023-00805-x.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Dexamethasone
  • Humans
  • Multiple Myeloma* / drug therapy
  • Neoplasms, Plasma Cell*

Substances

  • carfilzomib
  • daratumumab
  • Antibodies, Monoclonal
  • Dexamethasone

Associated data

  • ClinicalTrials.gov/NCT03412565
  • ClinicalTrials.gov/NCT01998971